Collegium Pharmaceutical
COLL
Cars.com
CARS
Halozyme Therapeutics
HALO
4
Lantheus
LNTH
5
Precision Drilling
PDS
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 3.24%262.79M | 12.23%1.04B | 7.36%255.8M | 11.84%266.68M | 14.85%265.32M | 15.18%254.55M | 21.07%928.73M | 20.27%238.26M | 20.36%238.44M | 20.37%231.02M |
Operating revenue | 3.24%262.79M | 12.23%1.04B | 7.36%255.8M | 11.84%266.68M | 14.85%265.32M | 15.18%254.55M | 21.07%928.73M | 20.27%238.26M | 20.36%238.44M | 20.37%231.02M |
Cost of revenue | -3.96%114.57M | 9.37%470.98M | 5.86%112.99M | 6.48%118.66M | 10.32%120.04M | 15.11%119.29M | 20.20%430.61M | 18.58%106.73M | 15.89%111.44M | 22.75%108.81M |
Gross profit | 9.58%148.22M | 14.71%571.37M | 8.58%142.81M | 16.55%148.02M | 18.88%145.28M | 15.23%135.27M | 21.83%498.11M | 21.67%131.52M | 24.58%127M | 18.32%122.2M |
Operating expense | 5.78%82.12M | 7.48%309.78M | 13.03%82.12M | -0.85%72.93M | 7.49%77.09M | 10.44%77.64M | 12.53%288.23M | 14.62%72.66M | 12.86%73.55M | 8.63%71.72M |
Selling and administrative expenses | 10.08%45.28M | 6.50%165.79M | 19.26%47.49M | -5.45%36.89M | 3.78%40.27M | 8.19%41.13M | 13.12%155.66M | 14.56%39.83M | 14.32%39.02M | 6.73%38.8M |
-Selling and marketing expense | 5.68%21.06M | 1.99%75.98M | 0.47%20.31M | -6.03%16.59M | 3.18%19.15M | 10.32%19.93M | 15.42%74.49M | 21.35%20.21M | 12.12%17.65M | 4.59%18.56M |
-General and administrative expense | 14.22%24.22M | 10.64%89.81M | 38.62%27.19M | -4.97%20.31M | 4.32%21.11M | 6.26%21.2M | 11.09%81.17M | 8.32%19.61M | 16.20%21.37M | 8.77%20.24M |
Research and development costs | 0.82%35.3M | 8.58%137.69M | 5.33%33M | 3.80%34.35M | 11.82%35.33M | 13.69%35.01M | 13.35%126.81M | 15.50%31.33M | 12.66%33.09M | 13.16%31.6M |
Depreciation amortization depletion | 3.22%1.54M | 9.54%6.3M | 8.37%1.63M | 17.22%1.69M | 12.80%1.49M | 0.40%1.49M | -13.67%5.75M | -0.07%1.51M | -13.46%1.44M | -24.40%1.32M |
-Depreciation and amortization | 3.22%1.54M | 9.54%6.3M | 8.37%1.63M | 17.22%1.69M | 12.80%1.49M | 0.40%1.49M | -13.67%5.75M | -0.07%1.51M | -13.46%1.44M | -24.40%1.32M |
Operating profit | 14.70%66.1M | 24.64%261.6M | 3.10%60.69M | 40.49%75.09M | 35.07%68.19M | 22.40%57.63M | 37.45%209.88M | 31.67%58.87M | 45.36%53.45M | 35.51%50.48M |
Net non-operating interest income expense | 13.67%6.03M | 789.93%5.3M | ||||||||
Non-operating interest income | ---- | 13.67%6.03M | ---- | ---- | ---- | ---- | 789.93%5.3M | ---- | ---- | ---- |
Other net income (expense) | -259.84%-1.59M | 46.43%-811K | 9.11%-4.03M | -24.55%1.31M | -12.20%914K | 596.50%996K | -131.38%-1.51M | -2,012.50%-4.44M | 7.88%1.74M | -53.59%1.04M |
Special income (charges) | ---2.93M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
-Less:Restructuring and merger&acquisition | --2.93M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | 34.24%1.34M | 46.43%-811K | 9.11%-4.03M | -24.55%1.31M | -12.20%914K | 596.50%996K | -131.38%-1.51M | -2,012.50%-4.44M | 7.88%1.74M | -53.59%1.04M |
Income before tax | 10.03%64.51M | 24.87%266.81M | 4.94%62.68M | 38.44%76.4M | 34.12%69.1M | 24.13%58.63M | 35.13%213.67M | 31.18%59.73M | 43.78%55.19M | 30.45%51.52M |
Income tax | 147.19%11.93M | 30.58%48.45M | 33.39%14.67M | 118.89%12.62M | 37.23%16.34M | -42.81%4.83M | 27.23%37.1M | 43.46%11M | -33.79%5.77M | 37.29%11.9M |
Net income | -2.27%52.58M | 23.67%218.36M | -1.48%48.02M | 29.06%63.78M | 33.18%52.77M | 38.69%53.8M | 36.92%176.57M | 28.70%48.74M | 66.55%49.42M | 28.53%39.62M |
Net income continuous Operations | -2.27%52.58M | 23.67%218.36M | -1.48%48.02M | 29.06%63.78M | 33.18%52.77M | 38.69%53.8M | 36.92%176.57M | 28.70%48.74M | 66.55%49.42M | 28.53%39.62M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -2.27%52.58M | 23.67%218.36M | -1.48%48.02M | 29.06%63.78M | 33.18%52.77M | 38.69%53.8M | 36.92%176.57M | 28.70%48.74M | 66.55%49.42M | 28.53%39.62M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -2.27%52.58M | 23.67%218.36M | -1.48%48.02M | 29.06%63.78M | 33.18%52.77M | 38.69%53.8M | 36.92%176.57M | 28.70%48.74M | 66.55%49.42M | 28.53%39.62M |
Basic earnings per share | -1.15%0.86 | 24.48%3.56 | 0.00%0.79 | 30.00%1.04 | 34.38%0.86 | 40.32%0.87 | 39.51%2.86 | 29.51%0.79 | 70.21%0.8 | 30.61%0.64 |
Diluted earnings per share | -1.16%0.85 | 24.47%3.51 | -1.28%0.77 | 30.38%1.03 | 34.92%0.85 | 38.71%0.86 | 38.92%2.82 | 30.00%0.78 | 68.09%0.79 | 28.57%0.63 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |